Product Images Capecitabine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Capecitabine NDC 83774-100 by Pilnova Pharma Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
StructuralFormula - ab3f3920 2554 4b1f b965 9b41035ab21b 01
Figure 1 Kaplan-Meier Estimates of Disease-Free Survival (All Randomized Population)a - ab3f3920 2554 4b1f b965 9b41035ab21b 02
This text seems to show the effectiveness of two treatment groups (5FU + LEUCOVORIN and CAPECITABINE) over a period of 96 months. The data appears to include the number of events occurring at each time point for both treatment groups. It could be related to a clinical trial or study comparing the outcomes of these treatment regimens.*
Figure 2 Kaplan-Meier Estimates of Overall Survival (All Randomized Population) - ab3f3920 2554 4b1f b965 9b41035ab21b 03
.. - ab3f3920 2554 4b1f b965 9b41035ab21b 04
This is an estimation of probability related to a medical treatment involving 5-FU, Leucovorin, and Capecitabine for a certain duration. The graph shows the probability values over specific time intervals in days. The treatment seems to have varying levels of probabilities at different time points.*
Figure 4 Kaplan-Meier Estimates for Time to Disease Progression Capecitabine and Docetaxel vs Docetaxel - ab3f3920 2554 4b1f b965 9b41035ab21b 05
Figure 5 Kaplan-Meier Estimates of Survival Capecitabine and Docetaxel vs Docetaxel - ab3f3920 2554 4b1f b965 9b41035ab21b 06
This text includes information related to the estimated probability of different treatment combinations involving Docetaxel, Capecitabine, and Widocetaxel administered over specific time intervals. The data seems to represent a chart with values ranging from 0.0 to 1.0 against time in days. It could be part of a medical or scientific analysis regarding the effectiveness or outcomes of these treatments over a certain period.*
150mg - ab3f3920 2554 4b1f b965 9b41035ab21b 07
The text provides information on a medication called capecitabine, which is presented in the form of film-coated tablets with 150 mg strength. It includes details on dosage recommendations, administration instructions, storage conditions, manufacturer details, and batch coding information. The medication is intended to be swallowed whole and not to be crushed or cut. It is important to dispense in tight containers and store at specific temperatures. Manufacturer details include Alembic Pharmaceuticals Limited and Pilnova Pharma Inc. This information is helpful for understanding the proper use and handling of capecitabine tablets.*
500mg - ab3f3920 2554 4b1f b965 9b41035ab21b 08
This text appears to be a medication label for Capecitabine tablets. It mentions the dosage and storage instructions for the tablets. The tablets contain 500 mg of capecitabine, USP, and should be swallowed whole without crushing or cutting them. The medication should be dispensed in tight containers and stored within certain temperature ranges. The label also provides batch coding and barcode information for reference.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.